Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase

다국어 초록 (Multilingual Abstract)

.

참고문헌 (Reference)

1 Nickel RS, "Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib" 62 : 2050-2051, 2015

2 Aksu T, "The remarkable response to ponatinib therapy in a child with blastic phase of chronic myeloid leukemia" 62 : 479-481, 2020

3 Hess G, "Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia : results of a prospective phase II open-label multicenter study" 23 : 7583-7593, 2005

4 Yamamoto M, "Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia" 60 : 85-87, 2018

5 Sasaki H, "Pre-and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation" 110 : 119-123, 2019

6 Gruner SE, "Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations" 36 : 514-519, 2019

7 Le Coutre PD, "Ponatinib in heavily pretreated patients with chronic phase chronic myeloid leukemia (CPCML): management of adverse events (AEs)" 122 (122): abst1496-, 2013

8 Millot F, "Ponatinib in childhood Philadelphia chromosome-positive leukaemias : an international registry of childhood chronic myeloid leukaemia study" 136 : 107-112, 2020

9 Cortes JE, "Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial" 132 : 393-404, 2018

10 Dorer DJ, "Impact of dose intensity of ponatinib on selected adverse events : multivariate analyses from a pooled population of clinical trial patients" 48 : 84-91, 2016

11 Rossoff J, "Experience with ponatinib in paediatric patients with leukaemia" 189 : 363-368, 2020

12 DeFilipp Z, "Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia" 16 : 466-471, 2016

13 Mahon FX, "Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib(STIM)trial" 11 : 1029-1035, 2010

14 de Bruijn CMA, "Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission : results of the STOP IMAPED study" 185 : 718-724, 2019

15 O’Hare T, "AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance" 16 : 401-412, 2009